Tag
Pharmaceuticals
59 articles
Pharmaceutical companies demonstrated mixed performance in the recent quarter, with IOL Chemicals reporting record revenue and profitability driven by strong demand in both its pharmaceutical and chemical segments. Conversely, Eris Lifesciences faced challenges in its international business due to supply chain disruptions and regulatory hurdles. Sector-wide, the Indian market showed resilience, with Pharma and Healthcare recording double-digit positive returns amidst broader market declines. These developments highlight the ongoing impact of global supply chain dynamics and regulatory landscapes on the pharmaceutical sector, suggesting continued volatility and the importance of operational efficiency for sustained growth.
Gujarat Themis Biosyn Incorporates Japanese Subsidiary
Gujarat Themis Biosyn discloses incorporation of wholly owned subsidiary Themis Biosyn Japan Limited pursuant to SEBI Regulation 30.
The new Japanese subsidiary received its Certificate of Registratio
Beryl Drugs Board Meeting Notice May 28
Beryl Drugs Ltd schedules its 2/2026-2027 board meeting for May 28, 2026, at its Indore registered office.
Agenda includes approval of audited FY26 financial statements and statutory auditor's report.
Parnax Lab Board Meeting on May 28, 2026
Parnax Lab Limited schedules board meeting on May 28, 2026, to approve Q4 and FY2026 audited financial results.
The meeting agenda includes consideration of standalone and consolidated IND-AS complian
D.C. Agencies vs Fenway Pharmaceuticals Adjournment Hearing
NCLAT adjourned hearing for Comp. App. (AT) (Ins) No. 218 of 2025 due to appellant's counsel request.
Appellant D.C. Agencies Pvt. Ltd. sought one week for better case preparation against respondent F
Viyash Scientific Q4 FY26 Earnings Call Recording
Viyash Scientific Limited disclosed availability of its Q4 FY26 earnings call audio recording pursuant to SEBI Regulation 30.
The earnings call was held on May 20, 2026 to discuss audited financial re
Indian Market Indices Mixed Returns May 2026
Broad market indices like Nifty 50 and Nifty 500 posted monthly declines of about 1‑2%, while mid‑cap and small‑cap gained 1‑3%.
Thematic indices delivered strong gains in Capital Markets (+7% TR, +6.
Morepen Labs Transfers 9% MML Stake to Business Head
Board approved transfer of 1.62 lakh MML shares to Head - Medical Devices for strategic alignment.
Company's stake in subsidiary Morepen Medipath reduced from 60% to 51% post-transaction.
Transaction
IOLCP Q4 Revenue Hits Record ₹619.5 Cr, PAT Up 68%
IOL Chemicals reported its highest-ever quarterly revenue of ₹619.5 crore in Q4 FY26, growing 17.4% YoY.
Profitability improved significantly with EBITDA at ₹94.3 crore (up 39.8% YoY) and PAT at ₹53.2
IOL Chemicals One-Day Shareholding Pattern Filing Delay
IOL Chemicals board addressed one-day delay in filing Q4 2025 shareholding pattern with BSE due to interpretational oversight.
Company paid ₹2,000 fine levied by BSE for the delayed filing submitted o
Innova Captab Attends 360 ONE Investor Conference
Innova Captab intimates schedule for its participation in the 360 ONE Capital 16th Annual Global Investor Conference.
Company officials will hold 1x1 and group meetings in Mumbai on 27th May 2026 star
Sanjivani Paranteral Q4 FY26 Earnings Call Transcript
Sanjivani Paranteral reported Q4 FY26 results impacted by Middle East export disruptions from Iran-US geopolitical conflicts in March.
The company's new Pune IV fluids facility contributed INR 2.7 cro
Hikal Board Meeting on May 27, 2026
• Hikal Ltd. schedules board meeting on May 27, 2026 to approve FY2026 audited financial results.
• Agenda includes consideration of standalone and consolidated results for quarter and year ended Marc
Hester Biosciences Africa Loan Terms Revised
Hester Biosciences executed amendments to its subsidiary's $12M Gates Foundation loan, reducing outstanding to $5M.
The amendments include a full waiver of accrued interest and removal of future inter
Strides Pharma Board Restructures Management Roles
Strides Pharma appoints Venkata Seetharama Raju Pakalapati as Executive Director and KMP effective June 1, 2026.
Aditya Arun Kumar transitions from Executive Director to Non-Executive Director, ceasin
Shaily Engineering Plastics Launches Semaglutide Pen Injector
Shaily Engineering Plastics announces regulatory approvals for its ShailyPen Neo™ device incorporated in generic Semaglutide injection.
The spring-driven pen injector platform received USFDA tentative
Dishman Carbogen Q4FY26 Net Revenue Up 18.9% YoY
Dishman Carbogen Amcis Ltd submitted its investor presentation on audited Q4FY26 and FY26 results to BSE and NSE per SEBI LODR Regulations 30 and 51.
Q4FY26 net revenue grew 18.9% YoY to ₹8,514 mn, wh
Eris Lifesciences Q4 FY26 Investor Presentation
Eris Lifesciences reported FY26 consolidated revenue growth of 8.1% to Rs. 3,129 crore and EBITDA growth of 10.1% to Rs. 1,120 crore.
The Domestic Branded Formulations (DBF) segment grew 11% with a 37
Lactose India FY26 Net Profit Rises to ₹6.06 Crore
Lactose India's board approved audited FY26 results with a net profit of ₹6.06 crore, a 17.4% increase from the previous year.
Revenue from operations for FY26 grew to ₹163.29 crore, a 40.3% increase
Astal Labs Subsidiary Appoints Khedar Ankur Auditors
Astal Laboratories discloses appointment of Khedar Ankur & Associates as statutory auditor for material subsidiary Sriven Pharmachem.
Appointment fills casual vacancy created by resignation of previou
Kimia Biosciences Board Meeting on May 29, 2026
Board meeting scheduled for May 29, 2026 to approve audited standalone financial results for Q4 and FY ended March 31, 2026.
Trading window closure continues until 48 hours after financial results dec
Coral Laboratories Board Meeting Scheduled May 30, 2026
Coral Laboratories intimates BSE of its upcoming board meeting on May 30, 2026, pursuant to SEBI LODR Regulation 29.
Agenda includes approval of FY26 standalone audited results and potential final div
Zydus Lifesciences Completes Torrent Urja 25 Investment
Zydus Lifesciences and subsidiaries invested Rs 90.18 million in Torrent Urja 25 equity shares on May 19, 2026.
The investment completes the four-tranche subscription totaling Rs 128.83 million for a
Gland Pharma Q4 FY26 Revenue Up 22% YoY
Gland Pharma reported Q4 FY26 revenue of INR17,428 million, a 22% YoY growth, with adjusted EBITDA at INR5,244 million (30% margin).
Full-year FY26 revenue reached INR64,307 million (14.5% growth), wi
NGL Fine-Chem Q4 FY26 Earnings Call Schedule
NGL Fine-Chem schedules earnings conference call for May 25, 2026 to discuss Q4 and FY26 operational and financial performance.
Management participants include Managing Director Rahul Nachane and Whol
Mankind Pharma Q4 Net Profit Rises to ₹713.61 Crore
Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, reporting ₹713.61 crore quarterly net profit.
Approved ₹500 crore additional investment in whol
ZIM Labs Q4 & FY26 EBITDA Down 16.4% YoY
ZIM Labs FY26 total operating income remained flat at ₹3,744 Mn, impacted by Mid-East war logistics and EU GMP audit deferral.
EBITDA declined 16.4% to ₹414 Mn with margins contracting 200 bps to 11.1
Zota Health Q4FY26 Earnings Call on May 25
Zota Health Care Ltd. will host an earnings call on May 25, 2026, to discuss Q4FY26 results announced on May 22.
Management participants include Founder Himanshu Zota, MD Moxesh Zota, and Group CEO Dr
Mankind Pharma FY26 Results, Board Decisions, Subsidiary Investment
Board approved audited standalone and consolidated FY26 results with revenue of ₹10,421.18 crore and net profit of ₹2,037.56 crore.
Approved additional investment of up to ₹500 crore in wholly-owned s
Zydus Lifesciences Promoters Intend to Participate in Buyback
Zydus Lifesciences intimates exchanges of its promoters' intention to participate in the company's ongoing share buyback.
The buyback is for up to 95.65 lakh shares (0.95% equity) at ₹1,150 per share,
SPARC Partner Ocuvex Receives FDA CRL for PDP-716
SPARC's licensing partner Ocuvex Therapeutics received a Complete Response Letter from the US FDA for its PDP-716 New Drug Application.
The FDA's CRL was issued solely due to inspection findings at th
Viyash Scientific FY26 Net Profit ₹759M, Approves ESOP
Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026.
Approved grant of 1.31 crore stock options to employees under new ESOP scheme 2026 at ₹101 per
Veeda Clinical vs Elite Pharma Arbitration Order
Supreme Court heard arbitration petition between Veeda Clinical Research Ltd and Elite Pharmaceutical Technology Co. Ltd on 18‑May‑2026.
Court ordered issuance of notice to respondents, returnable by
Bharat Parenterals Q4 FY26 Earnings Call Recording
• Bharat Parenterals Limited filed a SEBI Regulation 30 disclosure regarding its Q4 FY26 earnings conference call.
• The audio recording discusses the company's operational and financial performance f
Alivus Life Sciences Intimates Investor Meeting
Alivus Life Sciences discloses a one-on-one virtual investor meeting with Karma Capital scheduled for May 22, 2026.
The intimation is made pursuant to SEBI Listing Regulations 30 and Schedule III.
The
Ajanta Pharma Revises Analyst Meeting Schedule
Ajanta Pharma submits revised schedule for analyst and institutional investor meetings pursuant to SEBI Listing Regulations.
Corrects inadvertent date interchange for 360 ONE Capital conference on 29-
Vista Pharmaceuticals Board Meeting May 29 2026
• Vista Pharmaceuticals board meeting scheduled for May 29, 2026 to approve FY26 results.
• Meeting will consider audited financial results for quarter and year ended March 31, 2026.
• Board will revi
Vikram Thermo Board Meeting on May 26, 2026
Vikram Thermo schedules board meeting on May 26, 2026 to approve audited financial results for Q4 and FY ending March 31, 2026.
Board will consider recommending dividend for financial year 2025-26, su
Omkar Pharmachem MD Bhawani Shankar Goyal Name Change
Omkar Pharmacchem discloses managing director name change via SEBI Regulation 30 filing to BSE.
Bhawani Shankar Goyal's name changed to Bhawani S Goyal with no alteration in role or responsibilities.
Sai Parenterals Board Meeting Scheduled for May 23, 2026
Sai Parenterals Limited will hold a board meeting on May 23, 2026 to consider financial results.
Agenda includes unaudited Q3 and nine-month FY25 results, and audited FY26 annual results.
Meeting will
Hindustan Bio Sciences Board Meeting Intimation
Hindustan Bio Sciences Limited intimates exchange of board meeting scheduled for May 30, 2026.
Board to consider audited financial results for Q4 and FY ending March 31, 2026.
Meeting will also review
Kopran Limited FY26 Net Profit Declines 33% YoY
Kopran Limited reported a 33% YoY decline in consolidated net profit to ₹2,573.12 lakhs for FY26, with revenue up 8.2% to ₹68,142.36 lakhs.
Board recommended a dividend of ₹3.00 per equity share (30%
Zydus Lifesciences Q4 Revenue Up 16% YoY, Announces Dividend and Buyback
Zydus Lifesciences reported Q4 FY26 revenue growth of 16.2% YoY to ₹75.87 billion and EBITDA growth of 20.2% to ₹25.54 billion.
The Board recommended a 100% dividend for FY26 and approved a share buyb
Zydus Lifesciences Q4 Revenue Up 16% YoY
Zydus Lifesciences reported Q4 FY26 revenue of ₹75,870 mn, a 16% YoY growth, with EBITDA margin expanding 110 bps to 33.7%.
The India branded formulations business grew 15% YoY, outperforming the mark
Lasa Supergenerics Board Meeting on May 29, 2026
• Lasa Supergenerics schedules board meeting on May 29, 2026 to approve audited financial results for Q4 and FY ending March 31, 2026.
• The trading window closure remains in effect until 48 hours aft
Blue Jet Healthcare Schedules Q4 FY26 Earnings Call
Blue Jet Healthcare intimates exchange of analyst call on May 25, 2026, to discuss audited standalone Q4 and FY26 results.
Management participants include MD Shiven Arora, COO V.K. Singh, CFO Ganesh K
Kwality Pharmaceuticals FY26 Revenue Up 36% to ₹503 Crore
Kwality Pharmaceuticals reported audited FY26 results with revenue of ₹503 crore, up 36% YoY, and PAT of ₹67.35 crore, up 69% YoY.
EBITDA margins expanded 200 bps to 24% driven by improved product mix
Strides Posts FY26 Earnings Call Recording
• Strides Pharma notified exchanges of audio recording availability for its May 18, 2026 earnings call discussing FY26 results.
• The call was held at 17:00 IST to review audited financial results for
IOLCP Q4 FY26 Earnings Call on May 22
IOLCP schedules analyst call for May 22 to discuss Q4 and FY26 financial results per SEBI Regulation 30.
Management participants include CFO, Company Secretary, Director Works, and Finance Advisor.
Ca
Bharat Parenterals FY26 Consolidated Loss ₹27.3 Cr
Bharat Parenterals reported consolidated FY26 revenue of ₹345.4 Cr with a PAT loss of ₹27.3 Cr, driven by subsidiary Innoxel's pre-commercial phase.
Innoxel Lifesciences secured USFDA and EU-GMP appro
Bharat Parenterals FY26 Results: Dividend, Loss Narrowing
• Board approved audited standalone and consolidated financial results for Q4 and FY ended March 31, 2026, with unmodified audit opinions.
• Recommended final dividend of ₹1.00 per equity share (10%)
Unjha Formulations Submits FY26 Integrated Financial Filing
Unjha Formulations submitted its integrated financial filing for Q4 and year ended March 31, 2026 to BSE.
The filing was made pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated D
Strides Pharma FY26 PAT Up 50% to ₹5,181m
Strides Pharma reported FY26 Operational PAT of ₹5,181m, a 50% YoY increase, with revenue growth of 6.4% to ₹48,587m.
EBITDA grew 15.3% to ₹9,253m, driven by 310bps gross margin expansion and strong 2
FDC Limited Receives US FDA ANDA Approval for Cefixime
FDC Limited received US FDA approval for its Abbreviated New Drug Application for Cefixime for Oral Suspension.
The approval covers two dosage strengths: 100 mg/5 mL and 200 mg/5 mL formulations.
This
Supreme Court Adjourns Lupin Settlement Petition
Supreme Court heard Special Leave Petition (Civil) No. 43989/2025 filed by O.S. Dilip Menon against Lupin Ltd.
Petition challenges the High Court of Madras judgment dated 20‑03‑2025 in WA No. 3475/202
IPC Organizes Indian Pharmacopoeia 2026 Scientific Conclave
IPC organized a scientific conclave on Indian Pharmacopoeia 2026 at NIPER Hyderabad focusing on reference and impurity standards.
The event brought together regulatory, industry, and clinical experts
Sun Pharma Receives Promoter Group Reclassification Requests for 1.8% Stake
Sun Pharma received requests on 14 May 2026 from three promoter group members seeking reclassification to public category.
The shareholders, Sudhir Valia, Raksha Valia, and Krishna Valia, collectively
Aptus Pharma Promoter Tejash Hathi Acquires 10,000 Shares
Promoter Tejash Maheshchandra Hathi discloses acquisition of 10,000 equity shares in Aptus Pharma Limited via off-market transaction on May 11, 2026.
The acquisition increases his total holding to 785
Ghanshyam Pansuriya Acquires 14,000 Aptus Pharma Shares
Promoter Ghanshyam Pansuriya disclosed acquisition of 14,000 equity shares in Aptus Pharma Limited via off-market inter-se transfer.
His total holding increased from 5.10% to 5.31% of the company's vo
Kapilbhai Chandarana Acquires 10,000 Aptus Pharma Shares
Kapilbhai Hasmukhbhai Chandarana, a promoter group member, acquired 10,000 equity shares of Aptus Pharma Limited on May 11, 2026.
The acquisition increased his total holding from 775,000 shares (11.30